Monoclonal Antibodies as a Therapeutic Strategy against Multidrug-Resistant Bacterial Infections in a Post-COVID-19 Era.

The development of severe multidrug-resistant bacterial infections has recently intensified because of the COVID-19 pandemic. According to the guidelines issued by the World Health Organization (WHO), routine antibiotic administration is not recommended for patients with supposed or confirmed mild SARS-CoV-2 infection or pneumonia, unless bacterial infection is clinically suspected. However, recent studies have pointed out that the proportion of non-essential antibiotic use in patients infected with SARS-CoV-2 remains high. Therefore, the silent pandemic of antibiotic resistance remains a pressing issue regardless of the present threats presented by the COVID-19 pandemic. To prevent or delay entry into the postulated post-antibiotic era, the long-term advocacy for the rational use of antibiotics, the optimization of infection control procedures, and the development of new antibacterial agents and vaccines should be underscored as vital practices of the antibacterial toolbox. Recently, the development of vaccines and monoclonal antibodies has gradually received attention following the advancement of biotechnology as well as enhanced drug discovery and development in cancer research. Although decent progress has been made in laboratory-based research and promising results have been obtained following clinical trials of some of these products, challenges still exist in their widespread clinical applications. This article describes the current advantages of antibacterial monoclonal antibodies, the development of associated clinical trials, and some perceived future perspectives and challenges. Further, we anticipate the development of more therapeutic agents to combat drug-resistant bacterial infections as well as to increase the resilience of current or novel agents/strategies.

First-principles prediction on antimony-doping effects on the cyclic stability of tin anodes for lithium-ion batteries.

Tin-based materials are considered as promising anode materials for advanced Li-ion batteries (LIBs) due to their relatively high capacity and suitable working voltage, but they suffer from poor structural stability during electrochemical cycling. Herein, we present the possibility that the cyclic stability of the Sn LIB anode can be enhanced by adding a small amount of antimony (Sb), based on first-principles investigation of lithiation behavior of amorphous Sn doped with 3 at% Sb. At low Li contents (x < 1.5 in a-LixSn0.97Sb0.03), our simulations show that the preferential reaction of Li with Sb over Sn tends to lead to the formation of small lithiated Sb clusters. However, the aggregated Sb, if any, become fully separated upon further lithiation, implying that they may remain well dispersed in the lithiation/delithiation process if the Sb-doping concentration is sufficiently low. The weak aggregation and preferential lithiation tendency of Sb in the Sb-doped Sn anode can be expected to contribute to enhancing its structural stability during cycling, in comparison with pure Sn and SnSb alloy cases. We also compare lithiation-induced changes in the electrochemical, transport and mechanical properties between the Sb-doped and pure Sn systems. Our study highlights the importance of low concentration and uniform distribution of Sb in order to obtain desired properties of Sb-doped Sn as an anode for LIBs. This finding also provides some hints for the further development of Sn-based anodes via fine-tuning of doping.